A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 11.25 EUR 2.27% Market Closed
Market Cap: 95.6m EUR

EV/EBIT
Enterprise Value to EBIT

-9.1
Current
4.6
Median
15.6
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-9.1
=
Enterprise Value
79.4m EUR
/
EBIT
-8.7m EUR
EBIT Growth EV/EBIT to Growth
DE
A
Apontis Pharma AG
XETRA:APPH
Average EV/EBIT: 1 869.7
Negative Multiple: -9.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
16%
1.1
CH
Roche Holding AG
SIX:ROG
14.2
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.9
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
194.1
21%
9.2
CH
Novartis AG
SIX:NOVN
14.8
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.3

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
57
2-Years Forward
EV/EBIT
14
3-Years Forward
EV/EBIT
7.9